|
Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer Clinical research trials and Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer. Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer clinical trial. Participants oftentimes recieve the finest healthcare available for their Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer  Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer
Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer
For Condition: Ovarian Neoplasms
Status: Recruiting
Sponsor(s): OSI Pharmaceuticals ,
Synopsis: The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria: - Confirmed relapsed ovarian cancer. - Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan). - One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin. - At least three weeks since prior chemotherapy and recovery from any related toxicities. - At least four weeks since prior radiotherapy and recovery from any related toxicities.
Total Enrollment: 80
Location and Contact Information:
Royal Surrey County Hospital *Recruiting*
Guildford, Surrey, , GU2 7XX
United Kingdom
Recruiting OSIP Information (800) 572-1932
The Sarah Cannon Cancer Center, Centennial Medical Center *Recruiting*
Nashville, Tennessee, 37203
United States
Recruiting OSIP Information 800-572-1932
Beatson Oncology Centre *Recruiting*
Glasgow, , G11 6NT
United Kingdom
Recruiting OSIP Information (800) 572-1932
Northern Centre for Cancer Research, Newcastle General Hospital *Recruiting*
Newcastle upon Tyne, , NE4 6BE
United Kingdom
Recruiting OSIP Information (800) 572-1932
Royal Marsden NHS Trust *Recruiting*
London, , SW3 6JJ
United Kingdom
Recruiting OSIP Information (800) 572-1932
Taunton & Somerset Hospital *Recruiting*
Taunton, , TA1 5DA
United Kingdom
Recruiting OSIP Information (800) 572-1932
St Chad's Unit *Recruiting*
Birmingham, , B18 7QH
United Kingdom
Recruiting OSIP Information (800) 572-1932
NYU- Kaplan Comprehensive Cancer Center *Recruiting*
New York City, New York, 10016
United States
Recruiting OSIP Information 800-572-1932
Mount Vernon Hospital *Recruiting*
Northwood, Middlesex, , HA6 2RN
United Kingdom
Recruiting OSIP Information (800) 572-1932
CRC Department of Medical Oncology *Recruiting*
Sutton Surrey, , SM2 5PT
United Kingdom
Recruiting OSIP Information (800) 572-1932
Medical Oncology Unit, Torbay District General Hospital *Recruiting*
Torquay, , TQ2 7AA
United Kingdom
Recruiting OSIP Information (800) 572-1932
Additional Information:
Study ID Numbers: 110-20;
Study Start Date: September 2002
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046800
Other Ovarian Neoplasms Studies:
1. Tariquidar and Docetaxel to Treat Patients with Lung, Ovarian, and Cervical Cancer
2. Pilot Study of ZD1839 (Iressa, Gefitinib) in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, or Cervical Cancer
3. Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
4. Study of T900607-sodium in previously treated patients with ovarian cancer.
5. Removal of the ovaries/fallopian tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
Related Studies:
Other Ovarian Neoplasms Clinical Trials
Other Clinical Trials
Other Birmingham Clinical Trials
Study of OSI-211 vs. Topotecan in Patients with Relapsed Epithelial Ovarian Cancer
|
|
|
|
|
|
|
|
